NEW YORK (GenomeWeb) – German molecular biology tools firm Sygnis announced yesterday that it has raised roughly €5.3 million ($5.9 million) in gross proceeds through a rights offering and subsequent private stock placement.

The funds, the company said, will be used for expenses associated with its planned €1.7 million cash-and-stock acquisition of UK-based proteomics reagents company Expedeon, as well as for one-time integration costs and working capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.